1. Home
  2. EVTC vs CAPR Comparison

EVTC vs CAPR Comparison

Compare EVTC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evertec Inc.

EVTC

Evertec Inc.

HOLD

Current Price

$27.35

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$26.10

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVTC
CAPR
Founded
1988
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2013
2011

Fundamental Metrics

Financial Performance
Metric
EVTC
CAPR
Price
$27.35
$26.10
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$35.80
$44.63
AVG Volume (30 Days)
715.8K
937.2K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
0.67%
N/A
EPS Growth
27.17
N/A
EPS
0.38
N/A
Revenue
$453,869,000.00
N/A
Revenue This Year
$12.68
N/A
Revenue Next Year
$6.86
$3.31
P/E Ratio
$69.16
N/A
Revenue Growth
11.48
N/A
52 Week Low
$21.81
$4.30
52 Week High
$37.79
$40.37

Technical Indicators

Market Signals
Indicator
EVTC
CAPR
Relative Strength Index (RSI) 60.55 41.34
Support Level $25.39 $25.48
Resistance Level $30.05 $30.21
Average True Range (ATR) 1.22 1.40
MACD 0.31 0.33
Stochastic Oscillator 81.86 22.85

Price Performance

Historical Comparison
EVTC
CAPR

About EVTC Evertec Inc.

Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: